Month: March 2012

Getting HIV Out of its Hiding Places – Reports from CROI 2012

 NATAP/CROI: HIV Eradication Study by DMargolis with Cancer Drug Here is link to webcast of the oral session at CROI called HIV Persistence, Latency, and Eradication where Dr David Margolis presented the results of the study he conducted which is discussed below: https://app2.capitalreach.com/esp1204/servlet/tc?c=10164&cn=retro&s=20481&&dp=player.jsp&e=16643&mediaType=podiumVideo from Jules Levin: The drug Zolinza used in this study appears to …

Getting HIV Out of its Hiding Places – Reports from CROI 2012 Read More »

Frailty & Muscle Loss Increase Mortality & Are Common in HIV+

Subject: NATAP/CROI: Frailty/Muscle Loss in HIV Increases Mortality & is Common NATAP https://natap.org/ _______________________________________________ Frailty & Muscle Loss Increase Mortality & Are Common in HIV+ from Jules Levin at CROI Live in Seattle. This poster session is a breakthrough in that it is identifying that muscle loss & frailty are fairly common in HIV+ persons & they …

Frailty & Muscle Loss Increase Mortality & Are Common in HIV+ Read More »

Pre-CROI HIV Cure Review Workshop Organized by Community Advocates- Meeting Notes

Thanks to Siegfried Schwarze, a research activist from  Germany, for writing down these notes from the meeting we had this past Sunday, March 4, 2012 in Seattle prior to CROI-2012. **************************************************************************** Sometimes the most important events don‘t take place at the conference itself but rather at  the surrounding workshops. This seemed to be the case this …

Pre-CROI HIV Cure Review Workshop Organized by Community Advocates- Meeting Notes Read More »

Report of This Weekend’s HIV Cure Workshop in Seattle

A couple of months ago a rag tag group of activist–including Project Inform (represented by myself), the Treatment Action Group (TAG) and the AIDS Treatment Activists Coalition (ATAC)–reached out to some of the world’s leading HIV researchers and companies working on HIV cure research and asked them to spend an entire day with us talking …

Report of This Weekend’s HIV Cure Workshop in Seattle Read More »

ViiV Announces Expanded Access of New Integrase Inhibitor…But Activists Are Concerned About Its Potential Misuse

The dolutegravir expanded access program (EAP) has been designed to provide free access to Shionogi-ViiV Healthcare’s investigational integrase inhibitor, dolutegravir (DTG, S/GSK1349572) in an open-label protocol program to adults living with HIV who have documented raltegravir or elvitegravir resistance, who have limited treatment options, and who require DTG to construct a viable antiretroviral regimen for …

ViiV Announces Expanded Access of New Integrase Inhibitor…But Activists Are Concerned About Its Potential Misuse Read More »

Scroll to Top